365 related articles for article (PubMed ID: 29481745)
1. Modulating Antibody-Drug Conjugate Payload Metabolism by Conjugation Site and Linker Modification.
Su D; Kozak KR; Sadowsky J; Yu SF; Fourie-O'Donohue A; Nelson C; Vandlen R; Ohri R; Liu L; Ng C; He J; Davis H; Lau J; Del Rosario G; Cosino E; Cruz-Chuh JD; Ma Y; Zhang D; Darwish M; Cai W; Chen C; Zhou H; Lu J; Liu Y; Kaur S; Xu K; Pillow TH
Bioconjug Chem; 2018 Apr; 29(4):1155-1167. PubMed ID: 29481745
[TBL] [Abstract][Full Text] [Related]
2. Linker Design Impacts Antibody-Drug Conjugate Pharmacokinetics and Efficacy
Su D; Zhang D
Front Pharmacol; 2021; 12():687926. PubMed ID: 34248637
[TBL] [Abstract][Full Text] [Related]
3. Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability.
Singh SK; Luisi DL; Pak RH
Pharm Res; 2015 Nov; 32(11):3541-71. PubMed ID: 25986175
[TBL] [Abstract][Full Text] [Related]
4. The Chemical Design and Synthesis of Linkers Used in Antibody Drug Conjugates.
Frigerio M; Kyle AF
Curr Top Med Chem; 2017; 17(32):3393-3424. PubMed ID: 29357801
[TBL] [Abstract][Full Text] [Related]
5. A Two-Step Immunocapture LC/MS/MS Assay for Plasma Stability and Payload Migration Assessment of Cysteine-Maleimide-Based Antibody Drug Conjugates.
Dong L; Li C; Locuson C; Chen S; Qian MG
Anal Chem; 2018 May; 90(10):5989-5994. PubMed ID: 29688004
[TBL] [Abstract][Full Text] [Related]
6. The Properties of Cysteine-Conjugated Antibody-Drug Conjugates Are Impacted by the IgG Subclass.
Datta-Mannan A; Choi H; Stokell D; Tang J; Murphy A; Wrobleski A; Feng Y
AAPS J; 2018 Sep; 20(6):103. PubMed ID: 30255287
[TBL] [Abstract][Full Text] [Related]
7. Attachment Site Cysteine Thiol pK
Vollmar BS; Wei B; Ohri R; Zhou J; He J; Yu SF; Leipold D; Cosino E; Yee S; Fourie-O'Donohue A; Li G; Phillips GL; Kozak KR; Kamath A; Xu K; Lee G; Lazar GA; Erickson HK
Bioconjug Chem; 2017 Oct; 28(10):2538-2548. PubMed ID: 28885827
[TBL] [Abstract][Full Text] [Related]
8. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].
Tsuchikama K
Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230
[TBL] [Abstract][Full Text] [Related]
9. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
Yamada K; Ito Y
Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
[TBL] [Abstract][Full Text] [Related]
10. Antibody-drug conjugates: recent advances in conjugation and linker chemistries.
Tsuchikama K; An Z
Protein Cell; 2018 Jan; 9(1):33-46. PubMed ID: 27743348
[TBL] [Abstract][Full Text] [Related]
11. Development of Novel Quaternary Ammonium Linkers for Antibody-Drug Conjugates.
Burke PJ; Hamilton JZ; Pires TA; Setter JR; Hunter JH; Cochran JH; Waight AB; Gordon KA; Toki BE; Emmerton KK; Zeng W; Stone IJ; Senter PD; Lyon RP; Jeffrey SC
Mol Cancer Ther; 2016 May; 15(5):938-45. PubMed ID: 26944920
[TBL] [Abstract][Full Text] [Related]
12. Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues.
Zhang D; Dragovich PS; Yu SF; Ma Y; Pillow TH; Sadowsky JD; Su D; Wang W; Polson A; Khojasteh SC; Hop CECA
Drug Metab Dispos; 2019 Oct; 47(10):1146-1155. PubMed ID: 31358513
[TBL] [Abstract][Full Text] [Related]
13. Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug Conjugates.
Burke PJ; Hamilton JZ; Jeffrey SC; Hunter JH; Doronina SO; Okeley NM; Miyamoto JB; Anderson ME; Stone IJ; Ulrich ML; Simmons JK; McKinney EE; Senter PD; Lyon RP
Mol Cancer Ther; 2017 Jan; 16(1):116-123. PubMed ID: 28062707
[TBL] [Abstract][Full Text] [Related]
14. Antibody structural integrity of site-specific antibody-drug conjugates investigated by hydrogen/deuterium exchange mass spectrometry.
Pan LY; Salas-Solano O; Valliere-Douglass JF
Anal Chem; 2015 Jun; 87(11):5669-76. PubMed ID: 25938577
[TBL] [Abstract][Full Text] [Related]
15. Development of Solid-Phase Site-Specific Conjugation and Its Application toward Generation of Dual Labeled Antibody and Fab Drug Conjugates.
Puthenveetil S; Musto S; Loganzo F; Tumey LN; O'Donnell CJ; Graziani E
Bioconjug Chem; 2016 Apr; 27(4):1030-9. PubMed ID: 26942771
[TBL] [Abstract][Full Text] [Related]
16. Custom-Designed Affinity Capture LC-MS F(ab')2 Assay for Biotransformation Assessment of Site-Specific Antibody Drug Conjugates.
Su D; Ng C; Khosraviani M; Yu SF; Cosino E; Kaur S; Xu K
Anal Chem; 2016 Dec; 88(23):11340-11346. PubMed ID: 27779866
[TBL] [Abstract][Full Text] [Related]
17. Chemical Site-Specific Conjugation Platform to Improve the Pharmacokinetics and Therapeutic Index of Antibody-Drug Conjugates.
Matsuda Y; Seki T; Yamada K; Ooba Y; Takahashi K; Fujii T; Kawaguchi S; Narita T; Nakayama A; Kitahara Y; Mendelsohn BA; Okuzumi T
Mol Pharm; 2021 Nov; 18(11):4058-4066. PubMed ID: 34579528
[TBL] [Abstract][Full Text] [Related]
18. Effect of attachment site on stability of cleavable antibody drug conjugates.
Dorywalska M; Strop P; Melton-Witt JA; Hasa-Moreno A; Farias SE; Galindo Casas M; Delaria K; Lui V; Poulsen K; Loo C; Krimm S; Bolton G; Moine L; Dushin R; Tran TT; Liu SH; Rickert M; Foletti D; Shelton DL; Pons J; Rajpal A
Bioconjug Chem; 2015 Apr; 26(4):650-9. PubMed ID: 25643134
[TBL] [Abstract][Full Text] [Related]
19. Universal Affinity Capture Liquid Chromatography-Mass Spectrometry Assay for Evaluation of Biotransformation of Site-Specific Antibody Drug Conjugates in Preclinical Studies.
Kotapati S; Passmore D; Yamazoe S; Sanku RKK; Cong Q; Poudel YB; Chowdari NS; Gangwar S; Rao C; Rangan VS; Cardarelli PM; Deshpande S; Strop P; Dollinger G; Rajpal A
Anal Chem; 2020 Jan; 92(2):2065-2073. PubMed ID: 31860282
[TBL] [Abstract][Full Text] [Related]
20. Linker technologies for antibody-drug conjugates.
Nolting B
Methods Mol Biol; 2013; 1045():71-100. PubMed ID: 23913142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
